The United Kingdom and the United States have signed a significant commercial pact that will maintain zero levies on UK medicine products going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to increase funding on medicines through the public health system. This commitment guarantees that tariffs on these crucial products will stay at zero for a timeframe of three years.
This agreement is in response to previous statements to dramatically increase import taxes on patented pharmaceutical products, with potential rates floated reaching 100%.
"This deal between the United Kingdom bolsters the worldwide climate for innovative medicines and brings long-overdue equity to American-British medicine commerce," an announcement noted.
Trade Importance
Drugs represent one of the Britain's most significant export categories to the United States, which is by far the primary market for major UK drugmakers.
Statistics indicate that in the 12 months to the end of the third quarter, the UK shipped drugs valued at £11.1bn to the US. This figure represented 17.4% of total UK exports in that period.
"This agreement secures jobs, stimulates funding and sets the stage for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Detailed UK Commitments
The deal entails several notable pledges from the UK:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a goal to increase total NHS spending on treatments from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum drug companies must refund to the NHS to control costs will be capped at fifteen percent. In the past, rebates topped 20%.
Recent Tensions
The deal takes place against a ongoing row between the drug companies and the UK government over drug pricing and approval rates.
These tensions were exacerbated by claims that American patients were charged several times more for the equivalent treatments than people in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been delayed or cancelled, while substantial investments have been announced toward projects in the United States.
A senior figure stated that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a share of its resources over the last ten years.
